Home >Product >Avatrombopag
CAS No.:570406-98-3
Molecular Formula:C29H34Cl2N6O3S2
Molecular Weight:649.65
PRODUCT NAME:Avatrombopag

Introduction: Welcome to the world of Avatrombopag, a groundbreaking pharmaceutical agent designed to address thrombocytopenia and support optimal health. Avatrombopag is a powerful thrombopoietin receptor agonist, known for its ability to stimulate the production and maturation of platelets in the body. Platelets are essential blood components responsible for clotting, and Avatrombopag plays a crucial role in maintaining platelet counts within a healthy range.

Understanding Thrombocytopenia: Thrombocytopenia is a medical condition characterized by abnormally low levels of platelets in the blood. Platelets are vital for clot formation, which helps prevent excessive bleeding and promotes wound healing. When platelet counts are insufficient, individuals are at a higher risk of bleeding complications and bruising. Avatrombopag serves as an invaluable tool in addressing thrombocytopenia, offering a safe and effective solution to bolster platelet production.

How Avatrombopag Works: Avatrombopag exerts its effects by binding to and activating the thrombopoietin receptor, which stimulates the production of platelets from bone marrow cells known as megakaryocytes. As platelets are produced and released into the bloodstream, Avatrombopag helps raise platelet counts, reducing the risk of bleeding events and improving overall health and well-being.

Benefits of Avatrombopag:

Thrombocytopenia Management: Avatrombopag is primarily used to manage thrombocytopenia in individuals with chronic liver disease who are undergoing medical procedures. It can help increase platelet counts before the procedure, reducing the need for platelet transfusions and mitigating bleeding risks.

Chronic Immune Thrombocytopenia (ITP): In patients with chronic ITP, Avatrombopag has shown promising results in raising platelet levels, providing a potential treatment option for those who do not respond well to other therapies.

Minimal Side Effects: Avatrombopag is generally well-tolerated, with minimal side effects reported during clinical trials. This makes it a safe and reliable choice for managing thrombocytopenia.

Ease of Administration: Avatrombopag is available in convenient tablet form, making it easy to administer and incorporate into a patient's treatment regimen.



Have Questions about Arshine Pharma?
Our professional sales team are waiting for your consultation.


Sign up to receive our weekly newsletter